Dr. Hunter Moore, a transplant fellow at the University of Colorado [Anschutz Medical Campus], is a study co-author. "Everyone is looking for ways to mitigate the threat of this disease, and there's a lot of investment and interest in new drugs," Moore said. "But if this disease gets out of control, those drugs won't have had safety evaluations. TPA has."